bloom burton & co. healthcare investor tsx: imv...immunovaccine’s business, and may not be...

© 2017 Immunovaccine Inc. All rights reserved.

Bloom Burton & Co. Healthcare

Investor Conference

TSX: IMV

May 2017

Forward-looking Statements

• Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Immunovaccine’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form. The forward-looking statements in this presentation are also based on a number of assumptions which may prove to be incorrect.

• Forward-looking statements contained in this presentation represent views only as of the date of this presentation and are presented for the purpose of assisting potential investors in understanding Immunovaccine’s business, and may not be appropriate for other purposes. Immunovaccine does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation.

• Investors are cautioned not to rely on these forward-looking statements and are encouraged to read Immunovaccine’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com.

2 © 2017 Immunovaccine Inc. All rights reserved.

DepoVaxTM

A new way to deliver messages to the immune sytem

Our approach fundamentally

transforms the way we

deliver messages to the

immune system

© 2017 Immunovaccine Inc. All rights reserved.3

Not the message but *how*

we deliver it is the key to

generating a pivotal immune

response against diseases

previously unresponsive to

immunotherapies

DepoVaxTM

has the potential to

revolutionize

Immunotherapy in

multiple areas

Value Proposition

Immunotherapy $100B market opportunity

Develop & Partner

Immuno Oncology Infectious diseases

Survivin

HPV E7

Malaria Zika

New applications

RSV

Head & Neck

Cervical

Ovarian

Anal

DLBCL

Melanoma

Lung…


TSX: IMV Investment Opportunity

• Focusing in Immuno-oncology

- Formulation/delivery platform (DepoVaxTM) and cancer target (survivin)

- Phase 1/1b with DPX-Survivac + Metronomic Oral Cyclophosphamide completed in 56 patients

- We are in our industry’s ”race of all time,” to increase the number of patients responding to immuno-

therapy beyond the current 20 percent industry average

- Triple combination with checkpoints inhibitors from Incyte and Merck (IDO1, PD-1 inhibitors)

- Three Phase 2 clinical trials and one Phase 1b ongoing in ovarian cancer and DLBCL

- Potential expansion in multiple other indications: breast, melanoma, lung, colorectal…


Investment opportunity

• Partners: Incyte, Merck, Merck Kga, Dana Farber Cancer Institute, UConn Health, Leidos, Zoetis

• DepoVax provides multiple opportunities of partnering: neo epitopes, infectious diseases vaccines (RSV, Malaria, Zika)

• Potential new applications with different products and diseases (eg: DNA, mRNA delivery, Allergies,…)

• Strong financial position

- Three set of clinical results reported in 2016

- Five clinical milestones projected in 2017 including pivotal results with Incyte in Q4

- Raised $16m in 2016 – cash to cover current business plan well beyond major clinical milestones to H2 2018

- TSX IMV: $1.50 (52 weeks Low: 0.51 - High:1.53) – Market cap: $175M


Immuno-oncology Platform & Product

• Formulation: DepoVax

- No water/No release: depot effect

- Protects the antigens and forces active uptake by immune cells

• Tumor Antigen: survivin

- Not just a flag on cancer but essential for survival of cancer cells

- Significant market potential across multiple indications


Cancer Survivin %

Ovarian 90

Breast 90

Melanoma 90

Lung 53

Colorectal 54

Gastric 94

Kidney 23-82

Glioblastoma 80

ALL 70

CML 70

MDS 90

DLBCL 60

Encapsulate in a Liposome

+ Lyophilize + suspend in oil

Combination Immunotherapy Opportunity

• T cell infiltration has emerged as the key component of immunotherapy efficacy

• Combination immunotherapy: a road map, JITC 2017 5:16

- Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

- Immuno-oncology making significant impact on cancer but not sufficiently active for many patients

- Anti-PD-1 pathway backbone in many combination strategies

- Extensive clinical benefit and tolerable side effects is so far unparalleled; there are no other compounds on the horizon that could take the place of PD-1 pathway inhibition for this purpose

- Emerging evidence that immune checkpoint blockade is effective primarily in tumors that are already recognized by the immune system, as manifest by a pre-existing CD8+ T cell infiltrate

- T cell activation vaccines and IDO1 inhibitors highlitghed




TIL+

Most likely to

benefit from

single-agent anti–

PD-1/L1

TIL -

Poor prognosis

Non responders

to single agent



Lung

Ovarian

Melanoma

Breast (TN)

Gastric

Bladder

Kidney

0 500,000 1,000,000 1,500,000

Anti PD-1 responders Non responders

Global Number of Patients diagnosed every year

Can

ce

r T

yp

e

Colorectal

Clinical Strategy Ovarian Cancer

Phase 1

Phase 1b

Strong sustained T cell

activation

Best dose regimen

Prime + boost

Increased expression of

checkpoint inhibitors

Clinical benefit POC

Triple

Combination

Trials with IDO

and PD-1

inhibitors

43% Tumor

shrinkage

High Level T

cells maintained

for a year


Phase 1b Combination Trial with Incyte

• Phase 1b combination (DPX-Survivac + epacadostat) in recurrent ovarian cancer

- Platinum resistant and sensitive subjects who have completed first-line treatment and have evidence of measurable disease

- Up to 40 with minimum of 16 evaluable patients, one arm, open-label, safety and efficacy study

- Company sponsored – Immunovaccine leading the trial with sites in US and Canada

- Interim results by the end of March

- Expected Completion: Q4 2017 (top-line results)

Endpoints

Primary: Safety, cell-mediated immunity, changes in immune cell infiltration from baseline tumor biopsy

to post-treatment tumor biopsies

Secondary: Response rate, time to progression, overall survival, biomarkers of immune and clinical

response

Immunovaccine Goal

Demonstrate DPX-Survivac can send CD8+ T cell to the tumor which with the help of IDO inhibitor can

be effective in reducing or eliminating the tumor



• Last week of March: Interim results on first 4 patients

• Patients with recurrent progressive disease - CT scans over one year with mandatory biopsies before and aftertreatment


Biopsies

CT Scan

Interim

Results

Anti PD-1

window of

Response


• Interim results on first 4 patients assessed after 2-3 months of treatment

- Safety (first in human triple combination with DPX-Survivac): no SAE

- Response Rate: 3 out of 4 with stable disease – one with progressive disease

- 75% Disease Control Rate

- Tumor shrinkage reported at day 140

- Survivin antigen-specific CD8+ T cell immune responses in the blood demonstrated

- Tumor immune profiling conducted on pre- and post-treatment biopsies

- Demonstrate increases in T cell infiltration in the tumors

- Markers of immune activation in the tumors including checkpoint inhibitors


Phase 2 Combination Trial with Merck

• Phase 2 combination (DPX-Survivac + pembrolizumab (anti-PD-1)) in recurrent ovarian cancer

- Platinum resistant subjects who have completed first-line treatment and have evidence of measurable disease

- 42 patients

- Funded by Merck - Investigator sponsored (Princess Margaret Hospital) - sites in Canada

- Initiation: Q2 2017


Endpoints

Primary: Overall response rate (ORR)

Secondary: Progression free survival (PFS) rate, overall survival (OS) rate, Number of side effects

IMV Goal

Demonstrate to Merck DPX-Survivac can send CD8+ T cells to the tumor and make it more responsive

to pembrolizumab – pembrolizumab has an efficacy (ORR) of 11% in ovarian cancer

Indication Product Trials Timing Partners

Ovarian DPX Survivac + mCPA Completed

DPX Survivac + mCPA + IDO1 Ongoing

DPX Survivac + mCPA + PD-1 Ongoing

DLBCL DPX Survivac + mCPAOngoing

DPX Survivac + mCPA + PD-1 Q1 2017 Large Pharma

HPV cervical

cancerDPX E7 First patient Q1

Pipeline


Phase 1/1b

Phase 2

Phase 2

Phase 1b

Phase 2

Phase 1/2

Indication Product Trials Timing Partners

RSV DPX-SHe AntigenTop line Results

October 2016

ZIKA/MALARIA Antigen Preclinical

Vet vaccines Contraception, BVDV Animal trials 2021 market

Partnering


Phase 1

RSV Phase 1 Clinical Results (12 Month Data)

• 23 amino acid peptide, Elderly population, 50ul dose volume


Step 2: DPX-RSV(A) (n=8)

0 100 200 300 400 5000

1

2

3

4

5

6

Study Day:

Vaccination:

En

dp

oin

t L

og

Tit

er

2017 Milestones


Milestones Expected date

RSV Phase 1 interim results July 2016

Phase 1/1b clinical results in ovarian cancer August 2016

First patient with Incyte in Ovarian cancer Sept 2016

RSV Phase 1 Final results 6 month data Oct. 2016

DPX-Neo (Uconn Health) preclinical results Oct. 2016

Combination trial with Merck Q1 2017

Interim clinical results with Incyte in Ovarian cancer Q1 2017

RSV Phase 1 Final results 12 month data Q2 2017

Interim clinical results from Dana Farber Cancer Institute in HPV cancers Q4 2017

Interim clinical results with Merck in Ovarian cancer Q4 2017

Top line clinical results with Incyte in Ovarian cancer Q4 2017

19

Management Team


Pierre Labbé, CPA Chief Financial Officer

25 years experience

Gabriela Rosu, MD Chief Medical Officer

16 years of experience

Rita Nigam, PhD Vice-President of Clinical

21 years experience

Leeladhar Sammatur, MSc Vice-President of Manufacturing

19 years experience

Marianne Stanford, PhD Vice-President of Research

13 years experience

Annie Tanguay, BSc Senior Director of Quality Assurance

15 years experience

Frederic Ors, MSc/MA Chief Executive Officer

19 years experience

http://vignette1.wikia.nocookie.net/logopedia/images/e/e8/Pharmacia_&_Upjohn.svg/revision/latest?cb=20100823162950

http://vignette1.wikia.nocookie.net/logopedia/images/e/e8/Pharmacia_&_Upjohn.svg/revision/latest?cb=20100823162950


Immunovaccine Inc.

1344 Summer Street, Suite 412

Halifax, Nova Scotia, B3H 0A8

Tel: 902.492.1819

Fax: 902.492.0888

bloom burton & co. healthcare investor tsx: imv...immunovaccine’s business, and may not be...

Documents